Novartis halts ALS drug development after mid-stage trial failure

Novartis has halted development of an experimental drug ​for amyotrophic lateral sclerosis after it failed to meet goals ‌in a mid-stage study, marking the latest disappointment for the Swiss drugmake...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。